Comprehensive estimates of diabetes prevalence and burden worldwide.
BioXcel stock craters after disclosure of investigator’s falsified safety report in Alzheimer’s study
BioXcel touted data Thursday morning claiming that Igalmi, its drug for agitation episodes, succeeded in a pivotal trial with Alzheimer’s patients, reducing a composite of